ACM
AVDL

Atika Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Atika Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-93,000
Closed -$1.59M – 63
2014
Q4 		$1.59M Buy
93,000
+31,000
+50% +$443K 1.16% 38
2014
Q3 		$887K Buy
62,000
+5,000
+9% +$71.9K 0.68% 54
2014
Q2 		$855K Buy
+57,000
New +$688K 0.7% 50

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Atika Capital Management's AVDL Position: Q1 2015 in Review

Atika Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2015, closing a stake of 93,000 shares — an estimated $1.59M sold.

Atika Capital Management first reported a position in AVDL in Q2 2014 and held it in 3 quarters. The position peaked at $1.59M in Q4 2014. 84 funds tracked by Wall St. Rank hold AVDL as of Q1 2015.

  • Atika Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Atika Capital Management sold 93,000 Avadel Pharmaceuticals shares in Q1 2015, an estimated $1.59M.
  • Atika Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Atika Capital Management's Avadel Pharmaceuticals position peaked at $1.59M in Q4 2014.
  • 84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2015.

Based on Atika Capital Management's 13F filing for Q1 2015, filed 15 May 2015.